Discussing Rheumatology: March 2022
Discussing Rheumatology: March 2022 by The Immune-Mediated Inflammatory Disease Forum
12 Huhti 202211min
Author Interview: Professor Roy Fleischmann
Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edit...
16 Maalis 202219min
Discussing Rheumatology: Tofacitinib safety and dose-switching in RA
Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib d...
24 Helmi 20227min
ACR1540 Ana Rita Cruz - Machado
ACR1540 Ana Rita Cruz - Machado by The Immune-Mediated Inflammatory Disease Forum
11 Helmi 20225min
ACR1087 Omar Alsaed
ACR1087 Omar Alsaed by The Immune-Mediated Inflammatory Disease Forum
11 Helmi 20225min
ORAL Surveillance Author Interview – Roy Fleischmann
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumato...
9 Helmi 202237min
Author Author Interview: Professor Kevin Winthrop
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Pr...
3 Helmi 202217min
Discussing Rheumatology: HZ and ILD with tofacitinib in RA
Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-...
27 Tammi 20226min
